| Jones, Robert |
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. |
|
|
| Recruiting | 2/3 | 30 | Europe | Vemurafenib, Zelboraf, Cobimetinib, Cotellic | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic | 10/29 | 10/29 | | |
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol |
|
|
| Recruiting | 2/3 | 825 | Europe | Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy | 10/29 | 10/29 | | |
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations |
|
|
| Recruiting | 2/3 | 30 | Europe | Trastuzumab, Herceptin, Pertuzumab, Perjeta | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm | 10/29 | 10/29 | | |
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition |
|
|
| Recruiting | 2/3 | 30 | Europe | Atezolizumab, Tecentriq | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma | 10/29 | 10/29 | | |
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers |
|
|
| Recruiting | 2/3 | 30 | Europe | Alectinib, Alecensa | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma | 10/29 | 10/29 | | |
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. |
|
|
| Recruiting | 2/3 | 30 | Europe | Entrectinib, Rozlytrek | Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche | Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma | 10/29 | 10/29 | | |
| Recruiting | 2 | 372 | Europe, Canada, Japan, US, RoW | disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA® | Seagen Inc., Merck Sharp & Dohme LLC | Urothelial Carcinoma | 11/26 | 05/28 | | |
FAKTION, NCT01992952: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer |
|
|
| Active, not recruiting | 1b/2 | 149 | Europe | AZD5363, Placebo, Fulvestrant | Velindre NHS Trust, AstraZeneca, Cenduit LLC, Covance, Cardiff and Vale University Health Board | Estrogen Receptor Positive Breast Cancer | 03/19 | 12/23 | | |
|
NCT04630262: ATTUNE Cementless FB Tibial Base Clinical Study |
|
|
| Terminated | N/A | 80 | US | ATTUNE Cementless CR Fixed Bearing, ATTUNE Cementless PS Fixed Bearing | DePuy Orthopaedics | Osteoarthritis of the Knee | 03/23 | 03/23 | | |
| Active, not recruiting | N/A | 357 | Europe, Canada, US, RoW | Merit WRAPSODY Endovascular Stent Graft, PTA | Merit Medical Systems, Inc. | Venous Stenosis, Venous Occlusion | 02/24 | 01/26 | | |
Mossie-GO, NCT06232954: Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda |
|
|
| Recruiting | N/A | 5600 | RoW | Mossie-Go containing treated transfluthrin disc, Mossie-Go containing untreated blank disc | Africa Power Limited, Malaria Consortium, ARCTECH INNOVATION LIMITED | Malaria, Mosquito-Borne Disease | 09/25 | 09/25 | | |
| Recruiting | N/A | 500 | Europe, RoW | Merit WRAPSODY Endovascular Stent Graft | Merit Medical Systems, Inc. | Venous Stenosis, Venous Occlusion | 12/25 | 07/27 | | |
NCT04907240: Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry |
|
|
| Recruiting | N/A | 614 | Europe | GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) | W.L.Gore & Associates | Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms, Trauma Injury | 10/26 | 10/35 | | |
| Lee, Siow M |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Shaw, Heather S |
| Recruiting | 2 | 850 | Europe | Tebentafusp, IMCgp100 | University of Oxford, Immunocore Ltd, Natera, Inc. | Melanoma (Skin), Melanoma, Uveal | 06/25 | 06/26 | | |
| Recruiting | 2 | 130 | Europe | SCIB1 or iSCIB1+ DNA vaccine | Scancell Ltd, Scancell Ltd | Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV | 01/26 | 01/26 | | |
| Recruiting | 2 | 82 | Europe, Canada, US, RoW | Darovasertib, IDE196, LXS196 | IDEAYA Biosciences | Uveal Melanoma | 01/26 | 01/29 | | |
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001 |
|
|
| Terminated | 2 | 1 | Europe | Biological: ATL001 | Achilles Therapeutics UK Limited | Melanoma, Advanced Non Small Cell Lung Cancer | 10/23 | 10/23 | | |
| Recruiting | 1/2 | 727 | Europe, Canada, US, RoW | Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors | Immunocore Ltd | Select Advanced Solid Tumors | 02/26 | 08/26 | | |
|
| Recruiting | 1 | 90 | Europe | NVG-111 | NovalGen Ltd. | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Malignant Melanoma | 12/23 | 12/25 | | |
| Ardeshna, Kirit |
| Completed | 3 | 462 | Europe, RoW | rituximab, No treatment | University College, London, Cancer Research UK, Roche Pharma AG | Lymphoma | 03/14 | 09/23 | | |
|
|
| Bridgewater, John A |
| Recruiting | 3 | 800 | Europe | Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine | UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament | Biliary Tract Neoplasms | 06/27 | 06/28 | | |
| Not yet recruiting | 2 | 72 | Europe | Ivonescimab, FOLFOX regimen | UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, Summit Therapeutics | Biliary Tract Cancer | 08/27 | 01/29 | | |
| Recruiting | 2 | 25 | Europe | Trastuzumab deruxtecan, Enhertu | University of Southampton, AstraZeneca, Natera, Inc. | Gastrooesophageal Cancer | 03/26 | 04/28 | | |
| McCormack, Mary |
NCT04081714: Intermediate Expanded Access Protocol CNMAu8.EAP03 |
|
|
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine, University of Texas, Southwestern Medical Center at Dallas | Multiple Sclerosis | | | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Roylance, Rebecca |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer |
|
|
| Recruiting | 2/3 | 780 | Europe | Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin | Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK | Breast Cancer | 06/24 | 06/34 | | |
| Active, not recruiting | 2 | 58 | Europe | Crizotinib Oral Capsule [Xalkori], Xalkori, Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic], Faslodex | Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now | Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation | 07/24 | 07/24 | | |
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression |
|
|
| Recruiting | 2 | 324 | Europe | Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib | Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche | Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer | 09/26 | 09/26 | | |
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 1100 | Europe | Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole | Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation | ER+ Breast Cancer, HER2-negative Breast Cancer | 09/27 | 09/30 | | |
| Recruiting | 1 | 45 | Europe | Palbociclib, Ibrance, Avelumab, Bavencio | Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now | Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer | 07/25 | 12/25 | | |
| Emmanuel, Anton |
NCT04707976: Comparing Transanal Irrigation With Navina Smart vs. Standard Bowel Care in Patients With Multiple Sclerosis |
|
|
| Recruiting | N/A | 92 | Europe | Navina Smart, Standard Bowel Care | Wellspect HealthCare, Wellspect HealthCare | Neurogenic Bowel (Disorder), Fecal Constipation, Fecal Incontinence, Multiple Sclerosis | 12/24 | 02/25 | | |
| DeSantes, Kenneth |
OPTIMUM, NCT03561259: A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects |
|
|
| Recruiting | 2 | 60 | US | 131I-MIBG, I-131 meta-iodobenzylguanidine, Iobenguane I-131 MIBG Injection, 131-MIBG + Vorinostat | Jubilant DraxImage Inc. | Neuroblastoma, Neuroectodermal Tumors, Neoplasms | 12/23 | 04/25 | | |
NCT04023331: 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma |
|
|
| Recruiting | 1/2 | 34 | US | 67Cu-SARTATE, Cu-67 SARTATE, copper 67 SARTATE, 64Cu-SARTATE, Cu-64 SARTATE, copper 64 SARTATE | Clarity Pharmaceuticals Ltd | Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma | 12/28 | 12/28 | | |
| Peggs, Karl |
| Recruiting | N/A | 150 | Europe, RoW | No Intervention | Takeda | Cytomegalovirus (CMV) | 04/25 | 04/25 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 06/26 | 06/26 | | |
| Recruiting | 1/2 | 55 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 03/25 | 09/26 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 190 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 08/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 1/2 | 470 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Active, not recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects |
|
|
| Completed | 1 | 80 | US | DS-7011a, Placebo | Daiichi Sankyo, Inc. | Systemic Lupus Erythematosus | 01/23 | 03/23 | | |
NCT05388903: A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 64 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 01/23 | 01/23 | | |
NCT05484414: Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA) |
|
|
| Not yet recruiting | 1 | 56 | US | SRP-3D (diethylamide), SRP-3D (DA), Placebo, Control | South Rampart Pharma, LLC | Pain | 12/25 | 03/26 | | |
NCT05583669: A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 24 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 05/23 | 05/23 | | |
NCT05633745: A Study to Assess NEU-723 in Healthy Participants |
|
|
| Terminated | 1 | 40 | RoW | NEU-723, Placebo | Neuron23 Inc. | Healthy | 06/23 | 06/23 | | |
| Recruiting | 1 | 85 | Europe, US | DS-9606a | Daiichi Sankyo | Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Germ Cell Tumor | 02/26 | 02/26 | | |
ZIRDOSE-CP, NCT05861778: Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma |
|
|
| Completed | 1 | 10 | RoW | 89Zr-Girentuximab, 89Zr-DFO-girentuximab, 89Zr-TLX250, TLX250CDx | Telix International Pty Ltd, Grand Pharmaceutical (China) Co., Ltd. | Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer | 11/23 | 11/23 | | |
KEYNOTE-797, NCT04042701: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 115 | Europe, US | Trastuzumab deruxtecan (DS-8201a), Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca UK Limited, Merck Sharp & Dohme LLC | Breast Cancer, Non-small Cell Lung Carcinoma | 12/24 | 08/25 | | |
NCT04894110: Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema |
|
|
| Active, not recruiting | 1 | 42 | US | EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose | Emmecell | Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation | 10/24 | 10/24 | | |
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 145 | Europe, Japan, US, RoW | Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced or Metastatic NSCLC | 06/25 | 06/25 | | |
|
|
| Recruiting | 1 | 210 | Japan, US | Valemetostat tosylate, DS-3201b, T-DXd, DS-8201a, ENHERTU, Dato-DXd, DS-1062a | Daiichi Sankyo | Advanced Solid Tumor | 11/28 | 11/28 | | |
NCT05755191: A Study to Assess NEU-411 in Healthy Participants |
|
|
| Completed | 1 | 147 | RoW | NEU-411, Placebo | Neuron23 Inc. | Healthy | 06/24 | 06/24 | | |
NCT05628961: Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics |
|
|
| Recruiting | 1 | 42 | US | HOPO 14-1 | SRI International | Toxicity;Chemical | 04/24 | 04/24 | | |
